Healthcare Industry News: Roche
News Release - February 20, 2014
ImmunoGen, Inc. Appoints Ellie Harrison as Chief Human Resources OfficerWALTHAM, Mass.--(Healthcare Sales & Marketing Network)--ImmunoGen, Inc. (IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Ellie Harrison as Vice President and Chief Human Resources Officer. Ms. Harrison brings to ImmunoGen more than thirty years of senior level Human Resources (HR) experience. She reports to Daniel Junius, President and Chief Executive Officer of ImmunoGen.
“Ellie joins us in a newly created position established to ensure that – as we progress – our talent, employee development and organizational structures support our successful advancement to the next stages,” commented Mr. Junius. “She brings extensive, strategic experience in HR and will play a key role in shaping ImmunoGen as we move forward.”
Ms. Harrison has led HR functions in organizations ranging from 40 to 8,000 employees. She joins ImmunoGen from Blue Cross and Blue Shield of Rhode Island (BCBSRI), where she was Senior Vice President of Human Resources, with responsibility for compensation and benefits, diversity and inclusion, talent management and acquisition, and employee engagement and development. Prior to joining BCBSRI, Ms. Harrison was Managing Director, Senior Human Resources Advisor at Citigroup, serving as head of HR for multiple lines of businesses within its global consumer banking division. Prior to joining Citigroup in 2009, Ms. Harrison held high level HR positions of increasing responsibility at Fidelity Investments, which she joined in 1997. Ms. Harrison’s career has also included senior HR positions at Chubb Life America, Banc One Asset Management Company and Healthsource, Inc. She is a graduate of the University of Minnesota.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company’s ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells; the Company has also developed antibodies with anticancer activity of their own. The most advanced compound with ImmunoGen’s ADC technology is Roche’s Kadcyla®, which is marketed in the US by Genentech and is also gaining approvals internationally. Additional compounds are in clinical testing by ImmunoGen and through the Company’s partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademarks of Genentech, a member of the Roche Group.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.